🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the fight against superbug strains of the bacteria, according to health experts.

A Global Public Health Issue

Gonorrhoea infections are on the rise around the world, with figures suggesting more than 82 million instances each year. Notably increased rates are reported in Africa and nations within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have reached a historical peak, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely advancement in the context of growing infection rates, the spread of superbugs and the highly restricted treatment choices at this time.”

Public health authorities are increasingly worried about the rise in treatment-resistant strains. The global health body has listed it as a "priority pathogen". A tracking program revealed that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Therapies Secure Clearance

Zoliflodacin, alternatively called a brand name, was approved by the US Food and Drug Administration in mid-December for combating gonorrhoea. This STI can lead to significant complications, including infertility. Scientists believe that specific application of this new drug will help delay the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This medication, which is also used to treat urinary tract infections, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a innovative non-profit model for drug creation. The charitable organization GARDP collaborated with the pharmaceutical company its industry partner to develop it.

“This approval represents a huge turning point in the management of superbug gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Testing Outcomes and Worldwide Availability

Based on data detailed in a prominent scientific publication, zoliflodacin eradicated over nine in ten of genital gonorrhoea infections. This establishes an equal footing with the existing first-line therapy, which combines an injection and a pill. The research involved hundreds of patients from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, GARDP has the rights to register and commercialise the drug in a wide range of developing nations.

Clinicians on the front lines have expressed optimism. Having a easy-to-administer therapy like this is seen as a "critical tool" for public health efforts. This is deemed crucial to reduce the burden of the illness for people and to halt the transmission of extremely resistant gonorrhoea globally.